AZ’s Durvalumab to Become New Treatment Option for Stage III NSCL Cancer: Oncologist

Wakayama Medical University Professor Nobuyuki Yamamoto Nobuyuki Yamamoto, deputy director of the School of Medicine, Wakayama Medical University, expressed his high hopes that AstraZeneca’s PD-L1 inhibitor durvalumab will become a new treatment option for patents with Stage III non-small cell...read more